Comparative Pharmacology
Head-to-head clinical analysis: TRIESENCE versus XENEISOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIESENCE versus XENEISOL.
TRIESENCE vs XENEISOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
XENEISOL is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
10 mg orally once daily, titrated to a maximum of 20 mg daily based on response and tolerability.
None Documented
None Documented
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Terminal elimination half-life is 4.5 hours (range 3.5-6 hours) in adults; prolonged to 8-12 hours in hepatic impairment.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Primarily hepatic metabolism followed by renal excretion of metabolites: 70% renal, 20% biliary/fecal, 10% unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid